Surveillance of the liver in type 2 diabetes: important but unfeasible?
Open Access
- 9 February 2024
- journal article
- review article
- Published by Springer Nature in Diabetologia
- Vol. 67 (6) , 961-973
Abstract
Fatty liver plays a pivotal role in the pathogenesis of the metabolic syndrome and type 2 diabetes. According to an updated classification, any individual with liver steatosis and one or more features of the metabolic syndrome, without excess alcohol consumption or other known causes of steatosis, has metabolic dysfunction-associated steatotic liver disease (MASLD). Up to 60–70% of all individuals with type 2 diabetes have MASLD. However, the prevalence of advanced liver fibrosis in type 2 diabetes remains uncertain, with reported estimates of 10–20% relying on imaging tests and likely overestimating the true prevalence. All stages of MASLD impact prognosis but fibrosis is the best predictor of all-cause and liver-related mortality risk. People with type 2 diabetes face a two- to threefold increase in the risk of liver-related death and hepatocellular carcinoma, with 1.3% progressing to severe liver disease over 7.7 years. Because reliable methods for detecting steatosis are lacking, MASLD mostly remains an incidental finding on imaging. Regardless, several medical societies advocate for universal screening of individuals with type 2 diabetes for advanced fibrosis. Proposed screening pathways involve annual calculation of the Fibrosis-4 (FIB-4) index, followed by a secondary test such as transient elastography (TE) for intermediate-to-high-risk individuals. However, owing to unsatisfactory biomarker specificity, these pathways are expected to channel approximately 40% of all individuals with type 2 diabetes to TE and 20% to tertiary care, with a false discovery rate of up to 80%, raising concerns about feasibility. There is thus an urgent need to develop more effective strategies for surveying the liver in type 2 diabetes. Nonetheless, weight loss through lifestyle changes, pharmacotherapy or bariatric surgery remains the cornerstone of management, proving highly effective not only for metabolic comorbidities but also for MASLD. Emerging evidence suggests that fibrosis biomarkers may serve as tools for risk-based targeting of weight-loss interventions and potentially for monitoring response to therapy. Graphical AbstractKeywords
Funding Information
- University of Helsinki
This publication has 77 references indexed in Scilit:
- Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy StudiesClinical Gastroenterology and Hepatology, 2015
- Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndromeThe Lancet Diabetes & Endocrinology, 2014
- A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liverJournal of Hepatology, 2013
- Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosisNature Reviews Gastroenterology & Hepatology, 2013
- Pathology of nonalcoholic fatty liver diseaseNature Reviews Gastroenterology & Hepatology, 2010
- Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistanceDiabetologia, 2007
- Overproduction of large VLDL particles is driven by increased liver fat content in manDiabetologia, 2006
- Fat Accumulation in the Liver Is Associated with Defects in Insulin Suppression of Glucose Production and Serum Free Fatty Acids Independent of Obesity in Normal MenThe Journal of Clinical Endocrinology & Metabolism, 2002
- Role of Reduced Suppression of Glucose Production and Diminished Early Insulin Release in Impaired Glucose ToleranceNew England Journal of Medicine, 1992
- HEPATIC GLUCOSE OUTPUT AND HEPATIC INSULIN SENSITIVITY IN DIABETES MELLITUSThe Lancet, 1951